Abstract:The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis and the meta-analysis of individual participant data reported by non-small cell lung cancer (NSCLC) Meta-analysis Collaborative Group in neo-adjuvant setting validated respectively that adjuvant and neoadjuvant chemotherapy would significantly improve overall survival (OS) and recurrence-free survival for resectable NSCLC. However, chemotherapy has reached a therapeutic plateau. It has been confirmed that epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeting therapy provides a dramatic response to patients with advanced EGFR-mutation positive NSCLC. Researchers have paid more attention to exploring applications of TKIs to early resectable NSCLCs. Several studies on adjuvant TKI treatment concluded its safety and feasibility. But there existed certain limitations of these studies as inference factors to interpret data accurately: the BR19 study recruited patients among which almost 52% had stage IB and only 15 (3.0%, 15/503) had been confirmed with EGFR-mutant type; retrospective studies performed at Memorial Sloan Kettering Cancer Center (MSKCC) selected EGFR mutant-type NSCLC patients but couldn't avoid inherent defects inside retrospective researches; the RADIANT study revised endpoints from targeting at EGFR immunohistochemistry (IHC)+ and/or fluorescence in situ hybridization (FISH)+ mutation to only EGFR IHC+ mutation, leading to selective bias; despite that the SELECT study validated efficacy of adjuvant TKI and second round of TKI after resistance occurred, a single-arm clinical trial is not that persuasive in the absence of comparison with chemotherapy. Taking all these limitations into account, CTONG1104 in China and IMPACT in Japan have been conducted and recruiting patients to offer higher level of evidences to explore efficacy of preoperative TKI therapy for early resectable EGFR mutation positive NSCLC patients (confirmed by pathological results of tumor tissue or lymph node biopsy). On the other hand, case reports and several phase II clinical trials with small sample size tried to elbow their way on respect of preoperative TKI treatment and advised that TKI tended to improve response rate. However, no data on survival rate was present. The first phase II study of biomarker-guided neoadjuvant therapy for stage IIIA-N2 NSCLC patients stratified by EGFR mutation status, sponsored by CSLC0702, showed erlotinib tended to improve response rate, but failed to show benefits of disease-free survival (DFS) or OS. Subsequently, CTONG1103 was designed to investigate efficacy of erlotinib vs. combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. All these ongoing trials should be worthy of our expect to provide convincing evidences for customized therapy for patients with resectable NSCLC.

Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.

OA07.06 Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.

Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients

Consolidative Local Ablative Therapy Improves the Survival of Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs.

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC Pts with Oligometastatic or Oligoprogressive Liver Metastases

Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study

First-line Continual EGFR-TKI Plus Local Ablative Therapy Demonstrated Survival Benefit in EGFR-mutant NSCLC Patients with Oligoprogressive Disease.

Continuing EGFR-TKI in Combination with Super-Selected Arterial Infusion Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR Positive Mutation Non-Small Cell Lung Cancer.

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy

Propensity Score-Matching Analysis of Local Consolidative Therapy for Patients with Oligometastatic Non-Small Cell Lung Cancer Without Progression after Front-Line Systemic Therapy

Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

Microwave Ablation As Local Consolidative Therapy for Patients with Extracranial Oligometastatic EGFR-mutant Non-Small Cell Lung Cancer Without Progression after First-Line EGFR-TKIs Treatment

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Local Therapy for Oligoprogressive Disease in Advanced Staged Non–small Cell Lung Cancer Patients Harboring Epidermal Growth Factor Receptor Mutation

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.

Local Therapy Combined with First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients with EGFR-Mutant Metastatic Non-Small Cell Lung Cancer

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

Clinical Efficacy Of Egfr-Tkis In Combination With Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer Harboring Egfr Mutations

Recursive Partitioning Analysis of Patients with Oligometastatic Non-Small Cell Lung Cancer: a Retrospective Study